Ainos, Inc. (AIMD) 是一家上市公司 属于 医疗保健 板块,经营于 生物科技 行业. 公司总部位于 San Diego, CA, 美国. 现任CEO为 Chun-Hsien Tsai.
AIMD 拥有 IPO日期为 2021-01-08, 44 名全职员工, 在 NASDAQ Capital Marke, 市值为 $6.89M.
Ainos, Inc., a healthcare company, engages in the developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. The company was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. Ainos, Inc. was incorporated in 1984 and is based in San Diego, California.